APNAR Pharma Acquires Aurex Laboratories
February 3, 2022
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
- Buyers
- APNAR Pharma LP
- Targets
- Aurex Laboratories
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Aurobindo Pharma USA Completes Acquisition of Lannett Company
June 30, 2026
Pharmaceuticals
Aurobindo Pharma USA Inc. (APUSA), a wholly owned subsidiary of Aurobindo Pharma Limited, has completed its acquisition of Lannett Company, Inc., USA from Lannett Seller Holdco, Inc. The deal received approval from the U.S. Federal Trade Commission on June 18, 2026, and effective June 29, 2026 Lannett became a wholly owned subsidiary of APUSA.
-
Parnell Acquires Noble Pharma LLC
April 11, 2026
Healthcare Services
Parnell announced it has acquired Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, under a Securities Purchase Agreement dated November 26, 2025. The deal adds an FDA- and DEA-accredited manufacturing facility in Menomonie, Wisconsin, to strengthen Parnell’s U.S. manufacturing capabilities and supply continuity.
-
Adragos Pharma Acquires Baccinex
February 6, 2025
Pharmaceuticals
Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.
-
Ampersand Capital Partners Majority Recapitalizes Phosphorex
August 25, 2022
Healthcare Services
Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.
-
Pfizer Acquires Amplyx Pharmaceuticals
April 28, 2021
Biotechnology
Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.
-
Pfizer's Hospital Business Acquires Arixa Pharmaceuticals
October 22, 2020
Pharmaceuticals
Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.